Thursday is delivering one of the most bifurcated sessions of 2026. The Nasdaq fell another 50+ points. Memory stocks declined despite blowout earnings beats. SpaceX’s historic lockup unlocked — and the market absorbed it. But in pockets of the tape, some of the biggest percentage moves of the entire year are playing out: a Hong Kong food holding company surging 500%, a communications tech firm tripling on a mystery filing, and SoundHound AI raising the bar for conversational AI monetization. Here are the 10 top stock gainers today – August 6, 2026.

The Thursday Market Context

Key context: Iran announced it reached an agreement with Oman on a proposed shipping route through the Strait of Hormuz — the first tangible Hormuz breakthrough. Crude oil is responding positively, while memory stocks (SNDK, MU) fall despite earnings beats, as profit-taking overwhelms fundamentals.

#1 — WYHG (Wing Yip Food Holdings Group Limited) | +179% to $9.33 (Benzinga) / +525.6% Intraday (StockMarketWatch)

Shares traded: 42.9 million | Catalyst: August 6 Extraordinary General Meeting resolution

Wing Yip Food Holdings is Thursday’s most explosive move — and the catalyst is not what most traders would expect.

The August 6 EGM Resolution: At today’s extraordinary general meeting, Wing Yip Food Holdings shareholders formally approved delegating authority to the board to issue new shares, bonds, and other securities — a vote that unlocks the company’s ability to raise capital on flexible terms.

Why did this trigger a 179-525% surge? The market is reading the EGM approval as a precursor to:

• A capital-raise that could fund acquisitions or geographic expansion
• A potential reverse merger or strategic combination announcement
• Enhanced balance sheet optionality at a company already trading well below intrinsic book value

The Balance Sheet That Makes This More Than Just a Squeeze:

StocksToTrade noted: “WYHG is not a balance-sheet stress story.” A company with $85.4M in cash, $104.5M in working capital, and only $14M in long-term debt, trading well below its $12.38 book value — that’s a value compression setup. When a catalyst arrives, the decompression can be violent.

Thursday’s trading behavior — 42.9 million shares on a stock that typically sees a fraction of that volume — confirms institutional and algorithmic interest, not just retail speculation.

#2 — CLRO (ClearOne Inc.) | +148% to +215% — The Mystery 8-K That Moved Everything

Catalyst: Strategic 8-K filing | Volume: Significantly above average

ClearOne surged between 148% (StockMarketWatch) and 215.4% (intraday high per StockMarketWatch live data) following a strategic 8-K filing — one of the most dramatic single-session moves from a communications technology company in recent market history.

What ClearOne does: It designs and manufactures professional audio and video conferencing solutions — microphone systems, beamforming arrays, video collaboration tools — for enterprise, government, and education markets.

The 8-K significance: In SEC filing language, an 8-K disclosing a “strategic” development can cover a range of material events: a major new contract, a merger or acquisition agreement, a licensing deal, a debt restructuring, or a partnership announcement. Without confirmation of the specific content, the market’s 148-215% reaction signals the filed event is perceived as fundamentally transformational.

The investment setup: ClearOne was already on momentum traders’ screens as a name with meaningful short interest and a track record of high volatility. The 8-K catalyst on top of existing technical positioning created the conditions for a sustained intraday squeeze — not just a brief spike.

Important note for traders: 8-K-driven moves of this magnitude are among the most reversal-prone events in micro-cap trading. The quality of the underlying development must be verified from the actual filing before assuming the move is durable.

#3 — CELZ (Creative Medical Technology Holdings Inc.) | +71-100%+ — Diabetes Patent Is the Real Deal

Price (premarket): $0.86 (+28.1%) | Session high: +100.5% | Volume: 25x average (StockMarketWatch)

Creative Medical Technology’s move is one of Thursday’s most legitimately substantiated — it is backed by a documented IP grant, not just a filing or social media narrative.

The Patent: CELZ received a Notice of Allowance for U.S. Patent: “SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS”

Why this is significant:

• The patent covers a novel approach to Type 1 diabetes immunotherapy — using exosomes derived from stem-cell-programmed myeloid cells to suppress the autoimmune response that destroys insulin-producing beta cells
• Type 1 diabetes affects approximately 1.9 million Americans and roughly 9 million people globally — with no cure currently available; existing treatments manage but don’t reverse the disease
• Exosome-based therapies represent one of the most promising emerging categories in regenerative medicine; major pharma companies have paid billions for early-stage exosome IP

The CELZ context: Earlier this year, AMIX (Autonomix Medical) surged 386% on a cancer-targeting patent. The market’s consistent reaction to meaningful IP grants from clinical-stage micro-caps is now an established August 2026 pattern. CELZ’s 25x volume surge confirms that retail and algorithmic traders have learned to respond to this category of catalyst.

Risk factor: A Notice of Allowance is not the same as a granted patent. It means the USPTO intends to grant the patent — but the formal issuance typically follows within a few months after payment of issue fees. The therapeutic value of the IP will take years of additional clinical development to monetize.

#4 — ENSC (Ensysce Biosciences Inc.) | +77% to $0.64 — Acquisition Plus $77M Financing

Catalyst: Announced acquisition of Cy Biopharma + private financing of up to $77 million

Ensysce Biosciences announced a double catalyst that is rare for a company at this price point: a strategic acquisition and a substantial new capital commitment in the same announcement.

The deal breakdown:

• Target: Cy Biopharma — a biopharmaceutical developer
• Financing: Up to $77 million in private financing — providing runway for integration and development pipeline advancement
• Strategic rationale: Ensysce’s core focus is on abuse-deterrent opioid formulations and addiction treatment. Cy Biopharma’s pipeline adds complementary capabilities

For a company trading near $0.64/share, a $77 million capital commitment is transformative — it dramatically extends the company’s operational runway and validates investor confidence in the combined entity.

Risk: Integration of acquisitions at micro-cap stage companies carries significant execution risk. The $77M private financing structure (terms matter — equity vs. debt, dilution, warrants) will determine whether the capital is shareholder-friendly or dilutive.

#5 — SITM (SiTime Corporation) | +30.7% Pre-Market — Earnings Beat in Precision Timing

Pre-market gain: +30.7% | Catalyst: Q2 2026 earnings beat on both EPS and revenue

SiTime makes high-performance MEMS-based silicon oscillators and clocking systems for data centers, 5G base stations, automotive, and aerospace applications. In an AI data center buildout environment, precision timing hardware is non-optional — AI servers require ultra-stable clocking for synchronized multi-GPU workloads.

Q2 results: Beat both analyst EPS and revenue estimates — specific figures indicate a significant upside surprise that the market has rewarded with a 30%+ premarket premium.

The SiTime positioning: As AI data centers demand ever-tighter performance tolerances, the semiconductor components that enable nanosecond-level precision — timing ICs, crystal oscillators, resonators — are experiencing a structural demand upgrade. SiTime is the dominant pure-play in this space, and a clean earnings beat on both lines in this environment is a powerful validation of the thesis.

#6 — SOUN (SoundHound AI Inc.) | +23.1% to $7.91 Pre-Market — Beat and Raise Confirms AI Voice Monetization

Pre-market price: $7.91 (+23.1%) | Catalyst: Q2 2026 EPS beat + raised FY26 sales guidance with midpoint above estimates

SoundHound AI delivered exactly what the AI stock market desperately needed after a week of high-profile disappointments: a genuine beat-and-raise quarter.

What happened:

• Q2 2026 EPS: Beat analyst consensus
• Revenue: Beat analyst consensus
• FY26 Sales Guidance: Raised to levels with midpoint above analyst estimates — the most important number
• Business context: SoundHound’s voice AI platform is expanding into automotive (Honda, Stellantis), restaurant ordering systems, and enterprise contact centers

The AI monetization proof point: While names like Alphabet (Gemini delayed) and AMD (beat but fell) are creating doubt about AI execution, SoundHound’s beat-and-raise is a direct rebuke to the “AI hype over substance” narrative. Conversational AI is generating real, growing, recurring revenue at the application layer.

#7 — WPP plc | +22.6% to $25.31 Pre-Market — The Global Advertising Giant Shocks to the Upside

Pre-market price: $25.31 (+22.6%) | Catalyst: Q2 2026 earnings beat significantly above estimates

WPP is one of the world’s largest advertising, public relations, and marketing services groups. A +22.6% pre-market move for a company of WPP’s scale is an event-level beat — something went significantly right versus expectations.

What it signals for the sector:

• Digital advertising spending — including AI-powered campaign optimization, programmatic buying, and creator economy monetization — appears to be accelerating faster than expected
• WPP’s beat also benefits peers: Publicis, Interpublic (IPG), Omnicom
• SOUN’s beat confirms the AI application layer is monetizing; WPP’s beat confirms the advertising ecosystem that funds that application layer is also healthy

#8 — HNST (Honest Company Inc.) | +18.2% to $4.55 — Clean Consumer Brands Are Back

Pre-market price: $4.55 (+18.2%) | Catalyst: Stronger-than-expected Q2 results

Honest Company delivered better-than-expected Q2 results — a beat across both revenue and profitability metrics in the consumer packaged goods space.

Why it matters:

• Honest trades at a small market cap with a high short interest relative to its float
• A Q2 beat in consumer staples is particularly meaningful in the current environment, where “K-shaped” consumer weakness has been the dominant narrative (per StockMarketWatch’s midday note)
• Honest’s eco-conscious product positioning has been gaining shelf space at mass retail channels including Target and Amazon — a distribution expansion story that is flowing through to revenue

The squeeze mechanics: With elevated short interest and a genuine beat, HNST is experiencing short-covering on top of new buying — classic positive feedback loop.

#9 & #10 — MSFT and NVDA | Holding Ground in a Tech Selloff

MSFT: +1.8% | NVDA: +1.1% to $219.07

Both Microsoft and Nvidia — the two AI infrastructure anchors of the Magnificent Seven — are posting positive sessions while the broader Nasdaq slides. This is not a coincidence.

What the divergence signals:

• Capital is rotating within tech: away from capital-intensive hardware (memory, SpaceX capex) and toward productive AI software (MSFT’s Azure/Copilot) and AI chip design (Nvidia’s model)
• Nvidia’s +1.1% to $219.07 on a day when Micron fell 5.6% and SanDisk fell 13.1% suggests the market is differentiating between AI chip designers (winners) and AI chip manufacturers dealing with supply-demand normalization (pressured)

The Nvidia-SanDisk divergence is the clearest example: SanDisk blew past Q4 estimates — but guided Q1 below consensus. Nvidia’s AI compute thesis is about demand creation; SanDisk’s is about supply cycles. In August 2026, the demand creation story is being rewarded, and the supply cycle story is being sold.

Thursday’s Dominant Theme: Patents, 8-Ks, and Beaten Expectations

Today’s gainers share one key characteristic: each has a specific, documentable catalyst. WPP didn’t just go up — it beat earnings. CELZ didn’t just move — it received a patent allowance for diabetes immunotherapy. CLRO didn’t just surge — there’s an 8-K. This is what separates August 6’s gainers from pure speculation: every move has an anchor.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades.

_{^{Real-time gainers at StockMarketWatch Movers | Earnings calendar at TipRanks Earnings | CELZ patent at USPTO Patent Center}}

About The Author

Kasia Davis

See author's posts